Showing results (1-10 of 555) with videos related to
Sort By:
Pageof 56
Clinical Endocrinology|December 6, 2017
Multidisciplinary management of refractory insulinomasEmily Brown, Daniel Watkin, Jonathan Evans, et al.Peptides|February 8, 2018
Newer GLP-1 receptor agonists and obesity-diabetesEmily Brown, Daniel J Cuthbertson, John P WildingDiabetes, Obesity & Metabolism|May 14, 2019
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitorsEmily Brown, Surya P Rajeev, Daniel J Cuthbertson, et al.Lancet (London, England)|July 3, 2021
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indicationsEmily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, et al.Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|April 12, 2019
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilitiesEmily Brown, John P H Wilding, Thomas M Barber, et al.Annals of Medicine|October 27, 2020
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protectionEmily Brown, John P H Wilding, Uazman Alam, et al.Diabetologia|November 9, 2020
The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic reviewAikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, et al.Obesity (Silver Spring, Md.)|April 27, 2022
Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetesTom Waddell, Alexandre Bagur, Diogo Cunha, et al.Frontiers in Nutrition|March 5, 2021
The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?Theresa Hydes, Uazman Alam, Daniel J CuthbertsonClinical Medicine (London, England)|March 23, 2023
Diagnosis and management of neuroendocrine tumoursDaniel J Cuthbertson, Rebecca Shankland, Raj SrirajaskanthanPageof 56